In July 2009 we learned that Ness Ziona, Israel based Sol-Gel was trialing a supposed Benzoyl Peroxide derivate DER 45 EV for the treatment of rosacea.
Sol-Gel was granted Investigational New Drug Application for DER45-EV in November 2009, which allowed Sol-Gel to undertake Phase 2 Trials. DER45-EV has been licensed to a US based Pharmaceutical company (looks to be Merck) to further develop the drug and bring it to market.
It appears that DER45-EV is now being called encapsulated benzoyl peroxide (E-BPO).
The 5% formulation was found to be the most effective with 53% of participants being classed as clear or almost clear of rosacea symptoms. The average reduction in rosacea lesion count was 69%.
This is potentially good news for rosacea sufferers, especially those with stubborn papules and pustules that might benefit from a slow release form of benzoyl peroxide.
Ness Ziona, Israel, December 5, 2012 / B3C newswire / – Sol-Gel Technologies Ltd. announced today positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel. Although benzoyl peroxide is an established treatment for acne, until now it has not been used for the treatment of rosacea because it causes a high degree of skin irritation. Sol-Gel’s proprietary silica-based microencapsulation drug delivery system, successfully demonstrated in the study that it can ultimately provide a safe and effective first-in-class treatment.
The double-blind, randomized, vehicle-controlled, dose-range study was carried out at eight medical centers in the U.S. on 92 rosacea patients. The patients received one of two doses of E-BPO or a vehicle gel (control group). The length of the treatment was 12 weeks. The two tested doses were 1% and 5% E-BPO.
The primary objective of the study was to identify the lowest dose of E-BPO gel that demonstrates both safety and effectiveness in the treatment of rosacea.
There were two primary efficacy endpoints: the proportion of subjects with the primary measure of success, defined as a 2-grade improvement in the Investigator Global Assessment (IGA) relative to Baseline at Week 12, with patients at Week 12 IGA being clear or almost clear of symptoms; and the change in inflammatory lesion count at Week 12.
In the current study, 53 percent of the patients treated with doses of 5% E-BPO achieved the primary success criteria compared to 20 percent of the vehicle control group.
Reduction in mean inflammatory lesion count was 69 percent for the 5% E-BPO group compared to 33 percent in the vehicle control group.
5% E-BPO gel showed a favorable safety profile and was well tolerated.